Results 31 to 40 of about 16,883 (239)

Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice

Journal of Antimicrobial Chemotherapy, 2023
Objectives To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS)
I. Suárez-García, B. Alejos, V. Hernando, L. Viñuela, M. Vera García, D. Rial-Crestelo, M. P. Pérez Elías, H. Albendín Iglesias, J. Peraire, J. Tiraboschi, A. Díaz, S. Moreno, I. Jarrín   +12 more
semanticscholar   +1 more source

Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil

BMC Infectious Diseases, 2023
Background Since January 2017, the recommended first-line antiretroviral regimen in Brazil is the fixed-dose combination of tenofovir plus lamivudine with dolutegravir (TL + D).
R. Diaz, J. Hunter, M. Camargo, D. Dias, J. Galinskas, Isabela Nassar, Isaac Barbosa de Lima, Débora Bellini Caldeira, M. Sucupira, M. Schechter   +9 more
semanticscholar   +1 more source

Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants

bioRxiv, 2023
HIV-1 infection depends on the integration of viral DNA into host chromatin. Integration is mediated by the viral enzyme integrase and is blocked by integrase strand transfer inhibitors (INSTIs), first-line antiretroviral therapeutics widely used in the ...
Min Li, D. Passos, Z. Shan, Steven J. Smith, Qinfang Sun, A. Biswas, Indrani Choudhuri, Timothy S. Strutzenberg, A. Haldane, N. Deng, Zhaoyang Li, X. Zhao, T. Burke, Ronald M. Levy, S. Hughes, R. Craigie, D. Lyumkis   +16 more
semanticscholar   +1 more source

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function

Frontiers in Pharmacology, 2023
The implementation of combined antiretroviral therapy (cART) significantly reduces the mortality associated with human immunodeficiency virus (HIV) infection.
Chan Huang, Tozammel Hoque, R. Bendayan
semanticscholar   +1 more source

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation

Viruses, 2020
With the current widespread use of dolutegravir in low-income countries, the understanding of the impact of nucleoside reverse transcriptase inhibitor (NRTI-) associated mutations on the efficacy of dolutegravir-containing antiretroviral therapy (ART) is
Dominique L. Braun, Thomas Scheier, Ulrich Ledermann, Markus Flepp, Karin J. Metzner, Jürg Böni, Huldrych F. Günthard   +6 more
doaj   +1 more source

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]

Wellcome Open Research, 2021
Background: Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied ...
Zimasa Gcwabe, Kaneez Sayed, Charlotte Schutz, Olina Ngwenya, Eric Goemaere, Rene Goliath, Amanda Jackson, Rulan Griesel, Andrew Hill, Graeme Meintjes, Tali Cassidy, Claire Keene, Ying Zhao, Gary Maartens   +13 more
doaj   +1 more source

Weight gain during the dolutegravir transition in the African Cohort Study

Journal of the International AIDS Society, 2022
Dolutegravir (DTG) has become a preferred component of first‐line antiretroviral therapy (ART) in many settings but may be associated with excess weight gain.
A. Esber, David Chang, M. Iroezindu, E. Bahemana, H. Kibuuka, J. Owuoth, Valentine Singoei, Jonah Maswai, Nicole F Dear, T. Crowell, C. Polyak, J. Ake   +11 more
semanticscholar   +1 more source

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review

Viruses
Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk of emergent integrase strand transfer inhibitor (INSTI) drug ...
Carolyn Chu, Kaiming Tao, V. Kouamou, Ava Avalos, Jake Scott, Philip M Grant, Soo-Yon Rhee, S. McCluskey, Michael R. Jordan, Rebecca L. Morgan, Robert W. Shafer   +10 more
semanticscholar   +1 more source

Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir

AIDS Research and Therapy, 2023
Background Following reports of anti-retroviral therapy (ART) experienced Ugandan people living with HIV (PLHIV) presenting with diabetic ketoacidosis weeks to months following a switch to dolutegravir (DTG), the Uganda Ministry of Health recommended ...
Frank Mulindwa, B. Castelnuovo, N. Brusselaers, R. Bollinger, Joshua Rhein, Mutebi Edrisa, Allan Buzibye, Willington Amutuhaire, George Yendewa, S. Nabaggala, E. L. Odongpiny, Ronald Kiguba, Aisha Nakawooza, Simon Dujanga, Martin Nabwana, J. Schwarz   +15 more
semanticscholar   +1 more source